Barclays Lowers Elanco Animal Health (NYSE:ELAN) Price Target to $21.00

Elanco Animal Health (NYSE:ELAN) had its target price lowered by Barclays from $23.00 to $21.00 in a research note released on Friday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

Separately, Piper Sandler restated a neutral rating and issued a $19.00 target price (up previously from $18.00) on shares of Elanco Animal Health in a report on Monday, May 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $18.00.

Elanco Animal Health Trading Up 1.1 %

NYSE:ELAN opened at $14.43 on Friday. The company’s 50 day moving average price is $16.43 and its 200-day moving average price is $15.71. Elanco Animal Health has a 52 week low of $8.52 and a 52 week high of $18.80. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.95. The stock has a market cap of $7.13 billion, a price-to-earnings ratio of -5.45, a PEG ratio of 1.40 and a beta of 1.45.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.08. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the company posted $0.45 earnings per share. The firm’s quarterly revenue was down 4.1% on a year-over-year basis. On average, equities research analysts forecast that Elanco Animal Health will post 0.93 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other news, Director William F. Doyle acquired 15,000 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The shares were purchased at an average cost of $16.98 per share, for a total transaction of $254,700.00. Following the transaction, the director now directly owns 76,330 shares of the company’s stock, valued at $1,296,083.40. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.57% of the company’s stock.

Institutional Trading of Elanco Animal Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp bought a new stake in shares of Elanco Animal Health in the 4th quarter worth about $37,000. Global Financial Private Client LLC bought a new stake in shares of Elanco Animal Health in the 1st quarter worth about $72,000. Tower Research Capital LLC TRC boosted its stake in shares of Elanco Animal Health by 169.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock worth $93,000 after purchasing an additional 3,906 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Elanco Animal Health during the 3rd quarter worth about $95,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Elanco Animal Health during the 1st quarter worth about $167,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.